Global Ocular Ketorolac Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Ocular Ketorolac Market Size

• The global ocular ketorolac market size was valued at USD 32.10 million in 2024 and is expected to reach USD 50.24 million by 2032, at a CAGR of 5.76% during the forecast period
• The market growth is largely fueled by the increasing prevalence of ocular conditions such as post-operative inflammation, seasonal allergic conjunctivitis, and dry eye syndrome, which has created a strong demand for effective nonsteroidal anti-inflammatory drugs (NSAIDs) like ocular ketorolac
• Furthermore, rising consumer awareness about eye health, coupled with advancements in ophthalmic drug formulations, is establishing ocular ketorolac as a widely preferred treatment option in both hospital and retail pharmacy settings. These converging factors are accelerating the uptake of Ocular Ketorolac solutions, thereby significantly boosting the industry's growth

Ocular Ketorolac Market Analysis

• Ocular ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) used in ophthalmology, is increasingly vital in the management of post-operative eye inflammation, pain, and allergic conjunctivitis due to its effectiveness, safety profile, and widespread availability in both hospital and retail pharmacy settings
• The escalating demand for ocular ketorolac is primarily fueled by the growing prevalence of ocular disorders, rising awareness about preventive eye care, and increasing surgical procedures such as cataract and refractive surgeries where ketorolac is commonly prescribed.
• North America dominated the ocular ketorolac market with the largest revenue share of 40.00% in 2024, characterized by advanced healthcare infrastructure, high treatment adoption rates, and a strong presence of key pharmaceutical players, with the U.S. experiencing substantial growth in ocular ketorolac prescriptions, supported by ongoing research and new drug delivery innovations
• Asia-Pacific is expected to be the fastest growing region in the ocular ketorolac market during the forecast period due to increasing urbanization, rising disposable incomes, growing access to ophthalmic care, and an expanding patient base for both surgical and non-surgical ocular treatments
• The generic segment dominated the the ocular ketorolac market with the largest market revenue share of 62.4% in 2024, due to its affordability, wide availability, and preference in both developed and emerging markets. Cost-sensitive patients, particularly in regions with limited healthcare budgets, often opt for generics over expensive branded options

Report Scope and Ocular Ketorolac Market Segmentation   

Ocular Ketorolac Market Trends

Rising Adoption Driven by Increasing Prevalence of Ocular Disorders

• A significant and accelerating trend in the global ocular ketorolac market is the growing prevalence of ocular disorders such as postoperative inflammation, seasonal allergic conjunctivitis, and dry eye syndrome. This rise in eye-related conditions is significantly boosting the demand for anti-inflammatory ophthalmic drugs such as ketorolac, which provide effective pain and inflammation management
  • For instance, Ocular Ketorolac eye drops are increasingly being prescribed following cataract and refractive surgeries to control postoperative inflammation and reduce patient discomfort. Similarly, its role in treating allergic conjunctivitis has gained prominence, as it effectively mitigates itching and redness caused by seasonal allergens
• The growing adoption of Ocular Ketorolac is also supported by its cost-effectiveness compared to some newer therapies, making it accessible to a larger patient population, particularly in emerging economies. Moreover, rising awareness campaigns on eye health and early treatment of vision disorders are further driving its utilization across hospital pharmacies, retail pharmacies, and online channels
• The market is also benefiting from advancements in ophthalmic drug delivery systems, such as preservative-free formulations and single-dose vials, which improve patient safety and compliance. These innovations are ensuring a broader acceptance of Ocular Ketorolac among ophthalmologists and patients alike
• Furthermore, favorable government initiatives to improve ophthalmic care and rising investments in healthcare infrastructure are enhancing the availability of effective eye care treatments, including Ocular Ketorolac, across both developed and developing regions
• This trend towards greater reliance on proven ophthalmic anti-inflammatory drugs is fundamentally reshaping treatment protocols in eye care. Consequently, pharmaceutical companies such as Allergan, Sun Pharma, and Novartis are strengthening their portfolios with improved formulations and distribution strategies to meet the rising global demand for Ocular Ketorolac

Ocular Ketorolac Market Dynamics

Driver

Growing Need Due to Rising Prevalence of Eye Disorders and Post-Surgical Complications

• The increasing burden of ocular disorders such as cataracts, allergic conjunctivitis, and corneal abrasions, along with the high volume of ophthalmic surgeries worldwide, is a significant driver for the rising demand for ocular ketorolac formulations
  • For instance, in March 2023, the European Society of Cataract and Refractive Surgeons reported a substantial increase in cataract procedures across Europe, reinforcing the demand for effective post-operative pain and inflammation management. Such developments are expected to drive the growth of the Ocular Ketorolac market in the forecast period
• As patients and healthcare providers prioritize faster recovery, reduced complications, and improved surgical outcomes, ocular ketorolac provides targeted anti-inflammatory and analgesic benefits, making it an essential therapy in ophthalmic care
• Furthermore, the aging global population is leading to a sharp rise in cataract and refractive surgery cases, directly increasing the use of ocular ketorolac to manage post-surgical pain and swelling
• The convenience of multiple dosage forms such as ophthalmic solutions, gels, and preservative-free options enhances patient compliance and broadens adoption across hospitals, clinics, and ambulatory surgical centers. The growing awareness of ocular health and increasing availability of affordable generic ketorolac products are further contributing to the expansion of the market

Restraint/Challenge

Concerns Regarding Side Effects and Limited Access in Price-Sensitive Regions

• Safety concerns related to ocular ketorolac, including potential side effects such as delayed wound healing, corneal thinning, or ocular irritation, pose a significant challenge to its widespread use. Physicians often exercise caution in prescribing NSAID eye drops for patients with sensitive corneal conditions, which can restrain broader adoption
  • For instance, several clinical reviews in 2022 highlighted cases of corneal complications associated with prolonged or unsupervised use of ketorolac formulations, raising awareness among ophthalmologists about careful patient monitoring
• Addressing these safety concerns through improved formulation strategies, shorter treatment courses, and physician training is crucial for sustaining market confidence. Manufacturers are focusing on preservative-free, lower-concentration formulations to minimize risks and enhance tolerability
• In addition, the relatively high cost of branded formulations compared to generic alternatives can limit access, particularly in developing economies where healthcare budgets are constrained. While generics provide a cost-effective solution, their availability and regulatory approvals vary significantly across regions
• Overcoming these challenges through continuous clinical validation, expanding access to affordable generics, and increasing physician-patient education will be vital to ensuring the long-term growth of the Ocular Ketorolac market

Ocular Ketorolac Market Scope

The market is segmented on the basis of product/formulation, indication/application, end-user, and product type.

• By Product/Formulation

On the basis of product/formulation, the ocular ketorolac market is segmented into ophthalmic solution, ophthalmic gel/ointment, injectable/periocular formulations, and others. The ophthalmic solution segment dominated the largest market revenue share of 58.7% in 2024, as it remains the most widely prescribed formulation for treating post-operative ocular pain and inflammation. Its liquid form ensures rapid absorption, easy dosing, and broad adoption in both hospital and retail settings. The segment benefits from the availability of multiple generic versions, making it cost-effective and accessible to patients worldwide. Moreover, ophthalmic solutions are often the first-line therapy due to their high patient compliance and convenience in daily use. Regulatory approvals and inclusion in standard post-surgical protocols further strengthen its position. Its dominance is also reinforced by the continuous innovation in preservative-free solutions that improve tolerability for sensitive eyes. As a result, ophthalmic solutions will continue to remain the standard choice across most therapeutic settings.

The ophthalmic gel/ointment segment is anticipated to witness the fastest growth rate of 7.9% CAGR from 2025 to 2032, as gels and ointments provide longer ocular surface retention and sustained drug release, improving therapeutic outcomes. Their growing use in chronic conditions and severe inflammation cases is driving adoption among ophthalmologists. In addition, patients requiring nighttime application or prolonged relief prefer gel-based formulations for added comfort. Increasing R&D investments in advanced ophthalmic delivery systems are further expanding this segment’s growth potential. With rising demand for better ocular bioavailability, gels and ointments are gaining preference despite being slightly less convenient than drops. Expanding use in specialty ophthalmic clinics and niche therapeutic areas is also contributing to its robust growth. Thus, ophthalmic gels/ointments are emerging as an important alternative to traditional solutions.

• By Indication/Application

On the basis of indication/application, the ocular ketorolac market is segmented into post-operative ocular inflammation and pain, allergic conjunctivitis, corneal abrasions/ocular pain management, and others. The post-operative ocular inflammation and pain segment held the largest market revenue share of 49.3% in 2024, driven by the rising number of cataract, glaucoma, and refractive surgeries worldwide. The routine prescription of ketorolac after ocular surgery has made it an essential part of post-surgical care. Increasing patient awareness regarding pain management and faster recovery also boosts adoption in hospitals and ambulatory surgical centers. The segment benefits from strong physician preference due to the drug’s proven efficacy in reducing post-surgical inflammation. Growing geriatric populations, particularly in developed economies, are leading to higher surgery volumes and expanding market demand. In addition, favorable reimbursement for cataract procedures supports strong utilization of ketorolac in post-operative settings. As surgery rates continue to rise globally, this indication is expected to maintain its dominant position.

The allergic conjunctivitis segment is expected to witness the fastest CAGR of 8.2% from 2025 to 2032, fueled by the increasing prevalence of seasonal and perennial allergies. Rising urban pollution and changing environmental conditions are contributing to higher allergy cases worldwide. Ophthalmic ketorolac drops are gaining popularity as an effective, quick-relief option for reducing ocular itching, redness, and inflammation. Patients prefer ketorolac due to its non-steroidal profile, which minimizes the risks associated with long-term corticosteroid use. Growing adoption of OTC and prescription products in both developed and emerging markets is expanding patient reach. Pharmaceutical companies are focusing on developing preservative-free anti-allergy drops, which further supports market penetration. With rising awareness of eye health and a growing demand for self-care products, this indication is set for strong expansion.

• By End-User

On the basis of end-user, the ocular ketorolac market is segmented into hospitals, ambulatory surgical centers, ophthalmology clinics, and retail & online pharmacies. The hospitals segment accounted for the largest revenue share of 41.6% in 2024, as hospitals are the primary setting for ocular surgeries and acute treatments. Their access to advanced surgical infrastructure and trained ophthalmologists drives consistent prescribing of ketorolac. Hospitals also benefit from direct supply agreements with pharmaceutical companies, ensuring reliable availability of branded and generic products. The segment is further supported by higher patient inflow for cataract and refractive procedures, particularly among the elderly population. Post-surgical protocols in hospitals almost always include ketorolac, ensuring consistent demand. With the increasing number of hospital-based outpatient surgeries, utilization is expected to remain strong. The hospital segment’s dominance is also attributed to trust in regulated and clinically guided treatment environments.

The retail & online pharmacies segment is expected to witness the fastest CAGR of 9.1% from 2025 to 2032, owing to the growing convenience of digital purchasing and doorstep delivery. Rising internet penetration and increasing adoption of e-prescriptions are encouraging patients to purchase ketorolac through online platforms. The affordability and availability of generic versions are further boosting consumer preference for retail outlets and e-commerce channels. Patients managing allergies or chronic eye conditions find online access particularly appealing for repeat purchases. The rapid expansion of online pharmacy services in emerging economies is creating new growth opportunities. With better discounts, subscription models, and accessibility, the segment is capturing cost-conscious and tech-savvy consumers. This trend is expected to transform distribution channels and increase overall accessibility to ocular ketorolac.

• By Product Type

On the basis of product type, the ocular ketorolac market is segmented into branded and generic. The generic segment dominated the largest market revenue share of 62.4% in 2024, due to its affordability, wide availability, and preference in both developed and emerging markets. Cost-sensitive patients, particularly in regions with limited healthcare budgets, often opt for generics over expensive branded options. Widespread regulatory support and patent expiries of branded ketorolac formulations have fueled generic competition. Generics are also available across multiple distribution channels, from hospitals to retail and online pharmacies. Their proven equivalence in therapeutic efficacy has made them widely accepted by physicians and pharmacists alike. Governments encouraging generic prescriptions to reduce healthcare costs further contribute to strong adoption. This segment is expected to maintain its leading position over the forecast period.

The branded segment is anticipated to witness the fastest CAGR of 6.8% from 2025 to 2032, supported by strong brand loyalty among physicians and patients. Branded products are often perceived to have higher quality assurance, better packaging, and improved patient compliance. Companies continue to invest in preservative-free versions, single-use vials, and advanced formulations that differentiate branded ketorolac from generics. In premium healthcare settings, branded drugs remain the preferred choice due to trusted safety and efficacy profiles. Strategic marketing by leading pharmaceutical players also reinforces confidence in branded products. Additionally, the growing demand for innovative formulations in ophthalmic care supports the segment’s future growth trajectory.

Ocular Ketorolac Market Regional Analysis

• North America dominated the ocular ketorolac market with the largest revenue share of 40.00% in 2024, driven by the rising prevalence of cataract surgeries, increased cases of allergic conjunctivitis, and the growing geriatric population requiring ocular treatments
• Patients in the region benefit from strong healthcare infrastructure, wide availability of branded as well as generic formulations, and favorable reimbursement policies
• This strong adoption is further supported by high healthcare spending, advanced ophthalmology practices, and growing awareness about post-surgical eye care, establishing ocular ketorolac as a preferred therapy in both hospital and outpatient settings

U.S. Ocular Ketorolac Market Insight

The U.S. ocular ketorolac market captured the largest revenue share in 2024 within North America, fueled by the high number of cataract and refractive surgeries performed annually. Physicians and patients increasingly prioritize ocular ketorolac for its proven efficacy in reducing post-operative pain and inflammation. The expanding use of generic ketorolac formulations, along with the presence of major pharmaceutical companies and FDA approvals, further drives the market. Moreover, growing awareness campaigns on eye health and increasing access through retail and online pharmacies are significantly contributing to market expansion.

Europe Ocular Ketorolac Market Insight

The Europe ocular ketorolac market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by the rising demand for effective post-operative ophthalmic care and the increasing prevalence of allergic conjunctivitis. The growth of day-care surgeries and ambulatory centers, coupled with a large aging population, supports strong demand for ocular NSAIDs like ketorolac. European healthcare systems emphasize affordable access to generics, while ongoing research into preservative-free formulations further boosts adoption.

U.K. Ocular Ketorolac Market Insight

The U.K. ocular ketorolac market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by rising cataract surgery volumes under the NHS and growing awareness of effective post-surgical eye management. Concerns regarding ocular inflammation and allergic conditions are driving both physicians and patients to prefer ketorolac-based solutions. The country’s strong regulatory environment and widespread access to community pharmacies further stimulate market growth.

Germany Ocular Ketorolac Market Insight

The Germany ocular ketorolac market is expected to expand at a considerable CAGR during the forecast period, fueled by the country’s advanced healthcare infrastructure and high adoption of innovative ophthalmic solutions. Germany places strong emphasis on safety and patient outcomes, supporting the use of preservative-free and eco-conscious formulations. Increasing prevalence of age-related ocular disorders, alongside a well-developed hospital network, is boosting the demand for ocular ketorolac across both inpatient and outpatient segments.

Asia-Pacific Ocular Ketorolac Market Insight

The Asia-Pacific ocular ketorolac market is poised to grow at the fastest CAGR during the forecast period of 2025 to 2032, driven by a surge in ophthalmic surgeries, rising cases of ocular allergies, and increasing healthcare investments in countries such as China, Japan, and India. The region’s expanding middle-class population, rapid urbanization, and government initiatives promoting affordable eye care are further strengthening adoption. Availability of low-cost generic ketorolac and the expansion of domestic pharmaceutical manufacturers are making treatment more accessible to a wider patient base.

Japan Ocular Ketorolac Market Insight

The Japan ocular ketorolac market is gaining momentum due to the country’s advanced healthcare system, high surgical volumes, and strong focus on innovative ophthalmic therapies. With a rapidly aging population, cataract procedures are rising sharply, driving the demand for post-operative care solutions like ocular ketorolac. The Japanese market emphasizes patient convenience, with growing interest in preservative-free and easy-to-administer formulations, further fueling growth.

China Ocular Ketorolac Market Insight

The China ocular ketorolac market accounted for the largest revenue share in Asia Pacific in 2024, attributed to the country’s large patient pool, expanding healthcare access, and rising disposable incomes. China has become one of the most significant markets for ophthalmic drugs, supported by government-led initiatives for eye health and the presence of strong domestic manufacturers. Affordable generics, coupled with increasing surgical procedures and awareness campaigns, are key factors propelling the demand for ocular ketorolac in the region.

Ocular Ketorolac Market Share

The Ocular Ketorolac industry is primarily led by well-established companies, including:

• Caplin Steriles Limited (India)
• AbbVie Inc. (U.S.)
• Sunways India Pvt Ltd. (India)
• MICRO LABS LTD. (India)
• Ajanta Pharma Ltd. (India)
• Eyeris Vision Care Pvt. Ltd. (India)
• AdvaCare Pharma (U.S.)
• Omicron Pharma (India)
• Eurocrit Labs International (India)
• Santen Pharmaceutical Co., Ltd. (Japan)
• Zydus Lifesciences (India)
• Cycle Pharmaceuticals Limited (U.K.)
• Troikaa (India)
• Sun Pharmaceutical Industries Ltd. (India)

Latest Developments in Global Ocular Ketorolac Market

• In December 2023, industry reports highlighted the growing adoption of intraoperative ketorolac delivery, such as Omidria (ketorolac/phenylephrine), reflecting a shift in ophthalmic drug delivery practices away from traditional topical drops towards sustained or “dropless” alternatives
• In April 2024, Caplin Steriles Limited announced that it had received final US FDA approval for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Ophthalmic Solution 0.5%, a generic equivalent to ACULAR, designed for the treatment of ocular inflammation and pain
• In August 2025, PainReform announced the acquisition of a majority equity interest in LayerBio, with the goal of advancing OcuRing-K, a sustained-release ocular implant designed to deliver ketorolac during cataract surgery, offering a novel alternative to eye drops

SKU-74599